News
SPRO
2.260
-0.88%
-0.020
Weekly Report: what happened at SPRO last week (1124-1128)?
Weekly Report · 5d ago
Spero Therapeutics Grants 90,000 RSUs to New Employee Under Inducement Plan
Reuters · 11/28 13:00
SPERO THERAPEUTICS ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 11/28 13:00
Weekly Report: what happened at SPRO last week (1117-1121)?
Weekly Report · 11/24 09:51
Weekly Report: what happened at SPRO last week (1110-1114)?
Weekly Report · 11/17 09:51
Analysts Offer Insights on Healthcare Companies: Spero Therapeutics (SPRO), Kodiak Sciences (KOD) and VolitionRX (VNRX)
TipRanks · 11/17 06:50
Spero Therapeutics Focuses on Tebipenem HBr Program
TipRanks · 11/14 04:15
Spero Therapeutics Reports Q3 2025 Financial Results
TipRanks · 11/13 22:49
Spero Therapeutics GAAP EPS of -$0.13 beats by $0.12, revenue of $5.44M
Seeking Alpha · 11/13 21:13
Spero Therapeutics reports third quarter net loss of $7.4 million on revenue of $5.4 million
Reuters · 11/13 21:06
*Spero Therapeutics 3Q Loss $7.38M >SPRO
Dow Jones · 11/13 21:05
Press Release: Spero Therapeutics Announces Third -2-
Dow Jones · 11/13 21:05
*Spero Therapeutics 3Q Rev $5.44M >SPRO
Dow Jones · 11/13 21:05
Here are the major earnings after the close Thursday
Seeking Alpha · 11/13 15:00
Insights Ahead: Spero Therapeutics's Quarterly Earnings
Benzinga · 11/12 16:02
Weekly Report: what happened at SPRO last week (1103-1107)?
Weekly Report · 11/10 09:49
Spero Therapeutics Inc. to Report Third Quarter 2025 Financial Results
Reuters · 11/04 21:05
Weekly Report: what happened at SPRO last week (1027-1031)?
Weekly Report · 11/03 09:49
Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 26%
Simply Wall St · 10/29 10:47
Weekly Report: what happened at SPRO last week (1020-1024)?
Weekly Report · 10/27 09:51
More
Webull provides a variety of real-time SPRO stock news. You can receive the latest news about Spero Therapeuti through multiple platforms. This information may help you make smarter investment decisions.
About SPRO
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.